Evidence map›Paper›PMID 41826528›Full record

Observational studyDocumenta ophthalmologica. Advances in ophthalmology2026

Validation of a novel multi-luminance shape discrimination test for assessment of functional vision.

Andres Emanuelli, Benjamin Bakall, Byron L Lam, Charles C Wykoff, David Liao, Lance Bergstrom, Zak Vitaliy, Michael Carlson, Sanghoon Kim, Subrata Batabyal and 6 more

Abstract readValidation StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Documenta ophthalmologica. Advances in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andres EmanuelliEmanuelli Research and Development, 452 Ave. Rivera Aulet, Arecibo, PR, 00612, USA.
Benjamin BakallCollege of Medicine, University of Arizona, Phoenix, Associated retina Consultants, 1750 E Glendale Ave, Tucson, AZ, 85020, USA.
Byron L LamBascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL, 33136, USA.
Charles C WykoffRetina Consultants of Texas, 17450 Saint Luke's Way, Houston, TX, 77384, USA.
David LiaoRetina-Vitreous Associates Medical Group, 9001 Wilshire Blvd, Beverly Hills, CA, 90211, USA.
Lance BergstromBergstrom Eye and Laser Clinic, 2601 S University Dr, Fargo, ND, 58103, USA.
Zak VitaliyValley Retina Institute, 1309 E Ridge Rd STE 1, McAllen, TX, 78503, USA.
Michael CarlsonNanoscope Therapeutics Inc, 2777 N. Stemmons Fwy, Ste 1102, Dallas, TX, 75207, USA.
Sanghoon KimNanoscope Therapeutics Inc, 2777 N. Stemmons Fwy, Ste 1102, Dallas, TX, 75207, USA.
Subrata BatabyalNanoscope Therapeutics Inc, 2777 N. Stemmons Fwy, Ste 1102, Dallas, TX, 75207, USA.
Jean ChangNanoscope Therapeutics Inc, 2777 N. Stemmons Fwy, Ste 1102, Dallas, TX, 75207, USA.
John KoesterNanoscope Therapeutics Inc, 2777 N. Stemmons Fwy, Ste 1102, Dallas, TX, 75207, USA.
Mark Von TressNanoscope Therapeutics Inc, 2777 N. Stemmons Fwy, Ste 1102, Dallas, TX, 75207, USA.
Mark KosinskiQualityMetric Incorporated, LLC, 1301 Atwood Avenue, Suite 216E, Johnston, RI, 02919, USA.
Samuel B BaroneNanoscope Therapeutics Inc, 2777 N. Stemmons Fwy, Ste 1102, Dallas, TX, 75207, USA.
Samarendra K MohantyNanoscope Therapeutics Inc, 2777 N. Stemmons Fwy, Ste 1102, Dallas, TX, 75207, USA. smohanty@nanostherapeutics.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn low-vision patients, traditional measures often fall short of capturing functional vision improvements. The study aims to assess the reliability and validity of a novel functional low-vision outcome assessment, the Multi-luminance Shape Discrimination Test (MLSDT).

methodsThis is a prospective, observational study in 25 participants with severe vision loss due to retinitis pigmentosa (RP) with visual acuity worse than or equal to LogMAR 1.6, and in 10 normal vision participants. The MLSDT utilizes three differently shaped objects, randomly positioned on pressure sensors, to enable an automated, quantifiable response in a controlled multi-luminance environment. The assessment accuracy (recognizing the correct object and picking it up) was measured using the MLSDT. Convergent validity of MLSDT was evaluated with measures of visual acuity and visual field, as well as patient-reported outcomes.

resultsThe 35 study participants (60% male and 40% female) had a mean age of 46.5 years old (range: 19-78 years), with 24 Hispanic individuals. Estimates of test-retest reliability for MLSDT exceeded 0.50. The correlations between MLSDT test scores and LogMAR visual acuity were strong (> -0.7). For a difference of 0.3 LogMAR between the groups of RP participants, a decrease of ~ 2-level MLSDT score was observed. Moderate to strong correlations were also observed between MLSDT test scores and the measures of visual field and patient-reported outcome measures.

conclusionPsychometric evaluation demonstrates the reliability and validity of the novel functional vision endpoint, MLSDT. The MLSDT test performance in participants with different visual acuities showed improved object recognition when the luminance level was enhanced.

Indexed as

Form PerceptionRetinitis PigmentosaVision, LowVision TestsVisual AcuityVisual FieldsAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesReproducibility of ResultsYoung AdultFunctional visionObject recognitionRetinitis pigmentosaShape discrimination

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.